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Abstract 
Background: YWHAE is a possible susceptibility gene for schizophrenia that encodes 
14-3-3epsilon, a Disrupted-in-Schizophrenia 1 (DISC1)-interacting molecule, but the 
effect of variation in its genotype on brain morphology remains largely unknown.  
 
Methods: In this voxel-based morphometric magnetic resonance imaging study, we 
conducted whole-brain analyses regarding the effect of YWHAE single-nucleotide 
polymorphism (rs28365859) on gray matter volume in a Japanese sample of 72 
schizophrenia patients and 86 healthy controls. On the basis of a previous animal study, 
we also examined the effect of this genotype specifically on hippocampal volume.  
 
Results: Whole-brain analyses showed no significant effect of YWHAE genotype on 
gray matter volume in all subjects, but we found significant genotype-by-diagnosis 
interaction in the left insula and right putamen. The protective C allele carriers had a 
significantly larger left insula than the G homozygotes only for schizophrenia patients, 
while the controls with G allele homozygosity had a significantly larger right putamen 
than the C allele carriers. The C allele carriers had a larger right hippocampus than the 
G allele homozygotes in schizophrenia patients, but not in healthy controls.  
 
Conclusions: These different effects of the YWHAE genotype on brain morphology in 
schizophrenia and healthy controls suggest that variation in its genotype might be, at 
least partly, related to the abnormal neurodevelopment, including in the limbic regions, 
reported in schizophrenia. 
 
 
Keywords: DISC1; 14-3-3epsilon; Schizophrenia; Magnetic resonance imaging; 
Hippocampus; Insular cortex 
 
 
 
 
  
 3 
Introduction 
 
  Schizophrenia is a heterogeneous psychiatric disorder with a multifactorial etiology 
in which multiple susceptibility genes interact with environmental factors [1, 2]. 
Convergent evidence from neuroimaging studies in schizophrenia suggests subtle but 
widespread gray matter (GM) reductions predominantly in the frontal and temporo–
limbic regions (e.g., hippocampus), at least partly as a consequence of early 
neurodevelopmental insult [3, 4]. These brain morphologic changes in schizophrenia 
could be useful endophenotypes for unraveling the molecular etiopathology of this 
complex psychiatric disorder [5, 6]. 
  The Disrupted-in-Schizophrenia 1 (DISC1) gene [7, 8], which is thought to be 
involved in mechanisms of neurodevelopment and synaptic plasticity in cortical and 
limbic regions [9-13], has been one of the candidate genes for schizophrenia [14, 15]. In 
addition to the possible effect of DISC1 genotype variation on brain function and 
structure in the hippocampus [16] and cingulate cortex [17] in healthy subjects, our 
preliminary magnetic resonance imaging (MRI) study suggested that it might 
differentially affect GM volume of the neocortical and limbic regions in schizophrenia 
patients and healthy controls [18]. Several other MRI studies of DISC1 in schizophrenia 
have yielded inconsistent results [reviewed by Duff et al. [19]) and there have also been 
questions about DISC1 as a genetic risk factor of schizophrenia [20]. However, DISC1 
interacts with a complex formed by related molecules [13] and the genetic variation in 
such DISC1-interacting molecules might have a significant role in the pathophysiology 
of schizophrenia. 
  YWHAE is a gene encoding 14-3-3epsilon, one of the DISC1-interacting molecules 
that is thought to play a crucial role in neuronal development via transport of the 
NudE-like (NUDEL)/lissencephaly-1 (LIS1) complex [13, 21], and is a possible 
susceptibility gene for schizophrenia as identified in a Japanese population [22]. 
Genetic and expression evidence indicated that a functional single-nucleotide 
polymorphism (SNP) in the 5’ flanking region (rs28365859) was associated with 
schizophrenia, with subjects with the C allele having a reduced risk of the illness [22]. 
In addition, animal studies using genetically modified 14-3-3epsilon-deficient mice 
showed developmental defects of hippocampal neurons [21] as well as working memory 
deficits [22], which is one of the prominent features of schizophrenia [23]. Despite these 
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observations supporting the significant role of YWHAE in the neurobiology of 
schizophrenia, the possible association between variation in its genotype and brain 
morphology in schizophrenia remains largely unknown. 
  In this MRI study, we used voxel-based morphometry (VBM), which allows 
automated whole-brain analysis, to explore the effects of a YWHAE SNP (rs28365859) 
on regional GM volume in a Japanese sample of schizophrenia patients and matched 
healthy controls. On the basis of the potential role of YWHAE in neuronal development 
as well as previous MRI findings in schizophrenia [3, 4], we predicted significant 
diagnosis-by-genotype interaction predominantly in frontal and temporo–limbic regions, 
with patients with the protective C allele having a larger GM volume. As previous 
animal studies suggested the impact of YWHAE on the hippocampus [21], we also 
examined the effect of its genotype specifically on hippocampal volume using small 
volume correction (SVC) of VBM analyses, with the hypothesis that subjects with the C 
allele would have a larger hippocampal volume, especially in schizophrenia patients. 
 
Methods 
 
Ethics statement 
 
  This protocol was approved by Committee on Medical Ethics of Toyama University 
and Nagoya University Graduate School of Medicine. After a complete and detail 
description of the study was given, subjects provided written informed consent. Clinical 
staff explained the nature of the study to the subjects, the risks and benefits, and the 
option not to participate in this research. If the mental status of a subject was impaired 
to the point where s/he could not understand these issues, the subject was not asked to 
participate in this research. If there was a possibility that the capacity of a participant to 
consent was compromised, an additional consent form was obtained from the next of 
kin, care takers, or guardians of such subjects. 
Subjects 
 
  Seventy-two patients with schizophrenia (39 males and 33 females; mean age = 27.5 
years, SD = 6.0) who met the ICD-10 research criteria [24] were recruited from 
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inpatient and outpatient clinics of the Department of Neuropsychiatry of Toyama 
University Hospital. The patients were diagnosed following a structured clinical 
interview by psychiatrists using the Comprehensive Assessment of Symptoms and 
History (CASH) [25]. Clinical symptoms were rated at the time of scanning using the 
Scale for the Assessment of Negative Symptoms (SANS) [26] and the Scale for the 
Assessment of Positive Symptoms (SAPS) [27]. Sixty-eight patients were right-handed 
and four patients were mixed-handed. 
  The control subjects consisted of 86 right-handed healthy volunteers (45 males and 
41 females; mean age = 26.4 years, SD = 6.6) recruited from members of the local 
community, hospital staff, and university students. They were asked to complete a 
questionnaire consisting of 15 items concerning their personal (13 items; including a 
history of obstetric complications, substantial head injury, seizures, neurological or 
psychiatric disease, impaired thyroid function, hypertension, diabetes, and substance 
abuse) and family (2 items) histories of illness. Subjects with any personal or family 
history of psychiatric illness among their first-degree relatives were excluded. 
  All subjects were Japanese and physically healthy at the time of the study. None had 
a lifetime history of serious head trauma, neurological illness, serious medical or 
surgical illness, or substance abuse. All participants were also screened for gross brain 
abnormalities by neuroradiologists.  
 
 
SNP genotyping 
 
  Genomic DNA was extracted from EDTA-containing venous blood samples 
according to standard procedures. The genotyping of promoter SNP in YWHAE 
(rs28365859) was performed by direct sequencing using TaqMan assays (Applied 
Biosystems, Foster City, CA). TaqMan ® SNP Genotyping Assay and Universal PCR 
Master Mix were obtained from Applied Biosystems. Allelic-specific fluorescence was 
measured using the ABI PRISM 7900 Sequence Detector System (Applied 
Biosystems). 
 
MRI procedures 
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  MR images were obtained using 1.5T Magnetom Vision (Siemens Medical System, 
Inc., Erlangen, Germany) with a three-dimensional gradient-echo sequence FLASH 
(fast low-angle shots) yielding 160-180 contiguous T1-weighted slices of 1.0 mm 
thickness in the sagittal plane. The imaging parameters were as follows: repetition time 
= 24 ms; echo time = 5 ms; flip angle = 40º; field of view = 256 mm; and matrix size = 
256 x 256 pixels. The voxel size was 1.0 x 1.0 x 1.0 mm. The scanner was calibrated 
weekly with the same phantom to ensure measurement stability. 
  T1-weighted MR images were processed using Statistical Parametric Mapping 8 
(SPM8, Wellcome Institute of Neurology, University College London, UK, 
http://www.fil.icon.ucl.ac.uk/spm) running under MATLAB R2012b (The MathWorks 
Inc., USA). The images were preprocessed using the VBM8 toolbox 
(http://dbm.neuro.uni-jena.de/vbm/), which is an extension of the unified segmentation 
model consisting of spatial normalization, bias field correction, and tissue segmentation 
[28]. Registration to the stereotactic space of the Montreal Neurological Institute (MNI) 
consisted of linear affine transformation and nonlinear deformation using 
high-dimensional Diffeomorphic Anatomical Registration through Exponential Lie 
Algebra (DARTEL) normalization [29]. Estimation options were set as follows: 
extremely light bias regulation; bias cut-off full width at half maximum (FWHM) = 30 
mm; affine regulation = International Consortium for Brain Mapping (ICBM) space 
template of East Asian brains; and the others were defaults. The normalized and 
segmented images were modulated by applying a nonlinear deformation, which allows 
comparison of absolute amounts of tissue corrected for individual differences in brain 
size. The bias-corrected, modulated, and warped tissue maps were then written with an 
isotopic voxel resolution of 1.5 x 1.5 x 1.5 mm and smoothed with an 8-mm FWHM 
Gaussian kernel [30, 31] 
 
Exploratory whole-brain analysis of regional GM volume 
 
  First, we performed whole-brain analyses to explore the effects of YWHAE genotype 
and genotype-by-diagnosis interaction on GM volume in all subjects using the SPM8 
full factorial model, with age and sex as covariates of no interest. In order to avoid type 
I error, the significance level was set at p < 0.0001 (uncorrected for multiple 
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comparison), and the extent threshold of cluster size was set at k > 50.  
  Using the Wake Forest University (WFU) PickAtlas [32], we then performed small 
volume corrections (SVCs) for each brain region including the clusters with a 
significant genotype effect or interaction. Each region was defined using the Automated 
Anatomical Labeling (AAL) atlas [33]. For the regions of interest (ROIs) with 
significant genotype-by-diagnosis interaction, the effect of the YWHAE genotype was 
examined separately in the patients and controls, with age and sex as covariates of no 
interest. For these SVC analyses, a family-wise error-corrected (FWE) voxel level 
threshold of p < 0.05 was applied to account for multiple comparisons of the results. 
Voxel coordinates were given as an indication of location in a standardized brain. 
Voxels were localized in MNI space and transformed into Talairach and Tournoux 
coordinates [34] using the WFU PickAtlas [35, 36]. 
 
Hypothesis-driven ROI analysis for hippocampus 
 
  On the basis of a previous postmortem rat experiment [21], we also examined the 
effect of YWHAE polymorphism on bilateral hippocampi defined by the AAL atlas 
(FWE, p < 0.05). For this hypothesis-driven ROI analysis, we examined the effect of 
genotype in all subjects as well as in each diagnostic group. Age and sex were used as 
covariates of no interest in these analyses. 
 
Statistical analysis 
 
  Demographic and clinical differences between groups were examined by using 
chi-square test or one-way analysis of variance (ANOVA) with post hoc Scheffé’s test. 
Genotypes were tested for Hardy–Weinberg equilibrium (HWE) using the chi-square 
goodness-of-fit test. Since the number of subjects with C allele homozygosity was quite 
small (3 schizophrenia patients and 4 control subjects), and on the basis of a previous 
report on lymphocytes of healthy control subjects [22], the study participants were 
categorized into C allele carriers (protective allele group) or G allele homozygotes. 
Statistical significance was defined as p < 0.05. 
 
Results 
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Sample characteristics and genotyping results 
 
  Groups were matched for age, sex, height, body weight, and total GM volume, but 
the controls had attained a higher level of education than the schizophrenia patients 
(Table 1). There was no significant difference in clinical and demographic data between 
the C allele carriers and G allele homozygotes in both schizophrenia and control groups. 
The observed genotype frequency of SNP was within the distribution expected 
according to the HWE. As shown in Table 1, patients with schizophrenia and healthy 
comparisons did not differ significantly in genotype distributions (chi-square = 1.62, p = 
0.204) or allele frequencies (chi-square = 1.00, p = 0.317). 
Exploratory whole-brain analysis of regional GM volume 
  There was no significant main effect of YWHAE genotype on GM volume in all 
subjects. However, we found significant genotype-by-diagnosis interactions in the left 
insula and right putamen GM volume (uncorrected p < 0.0001, extent threshold k > 50; 
Table 2 and Fig. 1), which were confirmed by subsequent FWE-corrected SVC analyses 
(left insula, p = 0.004; right putamen, p = 0.001) (Table 2). 
  On the basis of these interactions, we then separately investigated the effect of 
YWHAE genotype on GM volume in schizophrenia and control groups. The protective 
C allele carriers had a significantly larger left insula than G homozygotes only for the 
schizophrenia patients (FWE-corrected p = 0.047, Fig. 2), while the controls with G 
allele homozygosity had a significantly larger right putamen than the C allele carriers 
(FWE-corrected p = 0.023, Fig. 3) (Table 2). The findings reported herein did not 
change even when we added the illness duration and medication dose as covariates for 
the SVC analyses for the schizophrenia patients (Table 2). 
Hypothesis-driven ROI analysis for hippocampus   
  The protective C allele carriers had a significantly larger right, but not left, 
hippocampal volume than the G allele homozygotes (FWE-corrected p = 0.009, Table 
3). For the analyses in each diagnostic group, such an effect of YWHAE genotype was 
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significant only in schizophrenia patients (FWE-corrected p = 0.009, Table 3 and Fig. 4). 
That result in schizophrenia remained the same even when we added illness duration 
and medication as covariates (Table 3).  
 
Discussion 
  This is the first structural MRI study to report the relationship between the functional 
polymorphism of YWHAE, a gene encoding 14-3-3epsilon, and brain morphology in 
patients with schizophrenia and healthy controls. While no significant difference was 
found in clinical and demographic data between the C allele carriers (protective allele 
group) and G allele homozygotes in both schizophrenia and control groups, the 
exploratory whole-brain analysis of regional GM volume demonstrated significant 
genotype-by-diagnosis interaction on the left insula and right putamen. Subsequent 
SVC analyses showed that the protective C allele carriers had a significantly larger left 
insula than G homozygotes only for the schizophrenia patients, while the controls with 
G allele homozygosity had a significantly larger right putamen than the C allele carriers. 
Furthermore, the hypothesis-driven ROI analysis revealed that the subjects with the C 
allele had a larger hippocampal volume, especially for schizophrenia patients. Our 
report using a Japanese cohort thus suggests that the genotype variation of 
14-3-3epsilon, a DISC1-interacting molecule associated with neuronal development [13, 
21], may be at least partly related to the abnormalities in brain morphology reported in 
schizophrenia. 
  Our finding of preserved insula GM volume in schizophrenia patients with the 
YWHAE protective C allele is consistent with the literature suggesting a significant role 
of insula pathology in schizophrenia [38]. GM reduction of the insula, which plays 
crucial roles in emotional and various cognitive functions as a component of the limbic 
integration cortex [39], has been repeatedly described in schizophrenia [40, 41]. GM 
reduction or dysfunction of the insula has also been implicated in the manifestation of 
psychotic symptoms and cognitive impairments [38]. The exact neurobiological basis 
for these GM changes of the insula in schizophrenia remains unknown, but the defects 
in gyrification [42], cytoarchitectural abnormalities [43, 44], and significant volume 
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reduction prior to the illness onset [45, 46] imply early neurodevelopmental 
abnormalities in this region. A lack of insular GM abnormalities in non-psychotic 
co-twins within monozygotic twins discordant for schizophrenia [47] suggests that the 
insular findings in schizophrenia are also attributable to non-genetic factors. Although 
our earlier MRI study demonstrated that the DISC1 genotype variation could differently 
affect the insula GM volume in schizophrenia patients and healthy comparisons [18], 
the current evidence for DISC1 alone as a genetic risk factor of schizophrenia is not 
strong [20]. However, considering that DISC1 interacts with a complex formed by 
related molecules (including 14-3-3epsilon) during processes involved in neuronal 
development, such as axonal elongation [13], the present results raise the possibility that 
the genetic variation of DISC1-interacting molecules might have an additive or 
independent role in alterations of the neural development in schizophrenia, especially 
regarding the insula pathology [38]. The potential role of genetic variation in 
DISC1-interacting molecules and its interaction with other genetic/non-genetic factors 
in the pathophysiology of schizophrenia should be further tested through in vitro and in 
vivo studies. 
  We also found significant YWHAE genotype-by-diagnosis interaction on the right 
putamen, with the C allele carriers having a smaller putamen volume only for healthy 
subjects. This finding might have some association with a previous MRI study that 
demonstrated the relationship between functional DISC1 genotype and striatal volume 
[48]. Taken together with animal data that the DISC1 gene influences striatal dopamine 
receptor levels [49], Chakravarty et al. [48] hypothesized that a key risk pathway for 
schizophrenia might be conferred via DISC1's effects on the striatum. MRI findings of 
the putamen in schizophrenia have been highly controversial; smaller [50] or normal 
[51, 52] volume was reported in first-episode antipsychotic-naïve patients, with both 
volume expansion [51, 53] and decrease [54] following antipsychotic treatment. We did 
not find a significant effect of the genetic variation of 14-3-3epsilon, a 
DISC1-interacting molecule, on the basal ganglia in our sample of chronically 
medicated schizophrenia patients. However, the possible role of genetic variation of 
DISC1 and its interacting molecules on brain morphology in schizophrenia should be 
examined in future, ideally using a larger antipsychotic-naïve sample. 
  In this study, as hypothesized, we also demonstrated that the subjects with the 
protective C allele had a larger hippocampal volume, especially for schizophrenia 
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patients. Hippocampal GM volume is thought to represent an endophenotype associated 
with the clinical expression of schizophrenia [55]. Brain imaging studies suggest that 
variants in the DISC1 gene may influence normal neurodevelopment, brain structure, 
function, and neurochemistry, but the association of the common DISC1 SNPs with 
hippocampal regions has been inconsistent for both schizophrenia and healthy subjects 
(reviewed by Duff et al. [19]). However, the expression of DISC1-binding partners such 
as NUDEL and LIS1, which form a complex with 14-3-3epsilon [13, 21], is reduced in 
the hippocampus of postmortem schizophrenia brains [56]. More specifically, animal 
studies using genetically modified 14-3-3epsilon-deficient mice showed developmental 
defects of hippocampal neurons [21] as well as behavioral changes related to clinical 
features of schizophrenia (i.e., anxiety-like behavior, working memory deficits) [22]. 
Schizophrenia is a complex disorder with a variety of pathologies and risk factor genes, 
and the variation of a single gene could explain only a part of its clinical expression. 
Nevertheless, the present and previous basic studies suggest the possibility that 
genetically defined impairment of DISC1 and/or 14-3-3epsilon could cause neuronal 
developmental defects in brain regions including the hippocampus, which result in the 
increased risk of developing schizophrenia. 
  There are several confounding factors in the present study. First, in contrast to recent 
large multinational consortium genome-wide association studies [57, 58], this study 
examined the effect of the YWHAE genotype only in a relatively small Japanese sample. 
Our whole-brain analysis found a specific YWHAE genotype effect only on the left 
insula in schizophrenia, but the current study was potentially underpowered to detect 
significant genotype effects on other brain regions owing to the small sample size. For 
example, an animal study by Sekiguchi et al. [59] suggested a relationship between the 
defect of 14-3-3epsilon and axon elongation abnormality in the prefrontal cortex. As we 
also found mild diagnosis-by-genotype interaction in frontal regions when we used a 
significance level of uncorrected p < 0.001 in exploratory whole-brain analysis (data not 
shown), future studies on a larger sample of schizophrenia might detect other YWHAE 
genotype effects on brain morphology including the frontal regions. Second, we 
examined schizophrenia patients with an illness duration of approximately 5 years in 
this study. Illness chronicity [60] and medication with antipsychotics [61, 62] could 
significantly affect brain morphology. Although there was no difference in these 
variables between the patients with and without the C allele (Table 1) and we 
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statistically controlled these factors, the present findings should be replicated using 
patients at early illness stages. Third, the current study cannot address the disease 
specificity of our YWHAE findings. There are overlapping GM structural abnormalities 
in the neurobiology of schizophrenia and bipolar disorder [63] and there are several 
susceptibility genes (e.g., DISC1) for both of these disorders [19]. Finally, we examined 
only a single polymorphism in one of the DISC1-interacting molecules in the present 
study. Further analyses of DISC1-related and other susceptibility genes as well as their 
interactions would be required to clarify the molecular etiopathology of this complex 
psychiatric disorder. 
  In conclusion, we found that the C allele of an SNP in YWHAE (rs28365859) is 
related to preserved GM volume of the insula and hippocampus in schizophrenia, major 
brain regions related to the illness, in a Japanese sample. These findings are likely to 
provide neurobiological support for previous genetic and expression studies suggesting 
that this SNP reduces the risk of schizophrenia [22]. Considering the limitations of the 
current study, further research is required to clarify the role of genetic variation of 
DISC1 and its interacting molecules in the pathophysiology of schizophrenia. 
  
 13 
Acknowledgements: The authors would like to thank all the participants in this study. 
We would also like to thank the radiological technologists, especially Mr. Koichi Mori 
and Mr. Sadanori Ito, who assisted in the MRI data collection at Toyama University 
Hospital. 
 
 14 
References 
1. Harrison PJ, Weinberger DR (2005) Schizophrenia genes, gene expression, and 
neuropathology: on the matter of their convergence. Mol Psychiatry 10: 40–68. 
2. Sawa A, Snyder SH (2002) Schizophrenia: diverse approaches to a complex disease. 
Science 296: 692–695.  
3. Shenton ME, Dickey CC, Frumin M, McCarley RW (2001) A review of MRI 
findings in schizophrenia. Schizophr Res 49: 1–52.  
4. Suzuki M, Nohara S, Hagino H, Kurokawa K, Yotsutsuji T, et al. (2002) Regional 
changes in brain gray and white matter in patients with schizophrenia demonstrated 
with voxel-based analysis of MRI. Schizophr Res 55: 41–54. 
5. Gottesman II, Gould TD (2003) The endophenotype concept in psychiatry: 
etymology and strategic intentions. Am J Psychiatry 160: 636-645. 
6. Keshavan MS, Prasad KM, Pearlson G (2007) Are brain structural abnormalities 
useful as endophenotypes in schizophrenia? Int Rev Psychiatry 19: 397-406.  
7. Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, et al. (2000) 
Disruption of two novel genes by a translocation co-segregating with schizophrenia. 
Hum Mol Genet 9: 1415-1423. 
8. St Clair D, Blackwood D, Muir W, Carothers A, Walker M, et al. (1990) 
Association within a family of a balanced autosomal translocation with major 
mental illness. Lancet 336: 13-16. 
9. James R, Adams RR, Christie S, Buchanan SR, Porteous DJ, et al. (2004) Disrupted 
in Schizophrenia 1 (DISC1) is a multicompartmentalized protein that predominantly 
localizes to mitochondria. Mol Cell Neurosci 26: 112–122. 
10. Kamiya A, Kubo K, Tomoda T, Takaki M, Youn R, et al. (2005) A 
schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. 
Nat Cell Biol 7: 1167–1178. 
11. Kirkpatrick B, Xu L, Cascella N, Ozeki Y, Sawa A, et al. (2006) DISC1 
immunoreactivity at the light and ultrastructural level in the human neocortex. J 
Comp Neurol 497: 436–450. 
12. Ozeki Y, Tomoda T, Kleiderlein J, Kamiya A, Bord L, et al. (2003) 
Disrupted-in-Schizophrenia-1 (DISC-1): mutant truncation prevents binding to 
NudE-like (NUDEL) and inhibits neurite outgrowth. Proc Natl Acad Sci U S A 100: 
289–294. 
 15 
13. Taya S, Shinoda T, Tsuboi D, Asaki J, Nagai K, et al. (2007) DISC1 regulates the 
transport of the NUDEL/LIS1/14-3-3epsilon complex through kinesin-1. J Neurosci 
27: 15–26. 
14. Ishizuka K, Paek M, Kamiya A, Sawa A (2006) A review of 
Disrupted-in-Schizophrenia-1 (DISC1): neurodevelopment, cognition, and mental 
conditions. Biol Psychiatry 59: 1189–1197. 
15. Roberts RC (2007) Schizophrenia in translation: disrupted in schizophrenia 
(DISC1): integrating clinical and basic findings. Schizophr Bull 33: 11–15. 
16. Callicott JH, Straub RE, Pezawas L, Egan MF, Mattay VS, et al. (2005) Variation in 
DISC1 affects hippocampal structure and function and increases risk for 
schizophrenia. Proc Natl Acad Sci U S A 102: 8627–8632. 
17. Hashimoto R, Numakawa T, Ohnishi T, Kumamaru E, Yagasaki Y, et al. (2006) 
Impact of the DISC1 Ser704Cys polymorphism on risk for major depression, brain 
morphology and ERK signaling. Hum Mol Genet 15: 3024–3033.  
18. Takahashi T, Suzuki M, Tsunoda M, Maeno N, Kawasaki Y, et al. (2009a) The 
Disrupted-in-Schizophrenia-1 Ser704Cys polymorphism and brain morphology in 
schizophrenia. Psychiatry Res 172: 128-135. 
19. Duff BJ, Macritchie KA, Moorhead TW, Lawrie SM, Blackwood DH (2013) 
Human brain imaging studies of DISC1 in schizophrenia, bipolar disorder and 
depression: a systematic review. Schizophr Res 147: 1-13. 
20. Sullivan PF (2013) Questions about DISC1 as a genetic risk factor for schizophrenia. 
Mol Psychiatry 18: 1050-1052.  
21. Toyo-oka K, Shionoya A, Gambello MJ, Cardoso C, Leventer R, et al. (2003) 
14-3-3epsilon is important for neuronal migration by binding to NUDEL: a 
molecular explanation for Miller-Dieker syndrome. Nat Genet 34: 274-285. 
22. Ikeda M, Hikita T, Taya S, Uraguchi-Asaki J, Toyo-oka K, et al. (2008) 
Identification of YWHAE, a gene encoding 14-3-3epsilon, as a possible 
susceptibility gene for schizophrenia. Hum Mol Genet 17: 3212-2322.  
23. Goldman-Rakic PS (1994) Working memory dysfunction in schizophrenia. J 
Neuropsychiatry Clin Neurosci 6: 348-357. 
24. World Health Organization (1993) The ICD-10 classification of mental and 
behavioural disorders: diagnostic criteria for research. World Health Organization, 
Geneva. 
 16 
25. Andreasen NC, Flaum M, Arndt S (1992) The Comprehensive Assessment of 
Symptoms and History (CASH). An instrument for assessing diagnosis and 
psychopathology. Arch Gen Psychiatry 49: 615-623. 
26. Andreasen NC (1984a) Scale for the assessment of negative symptoms (SANS). 
University of Iowa, Iowa City. 
27. Andreasen NC (1984b) Scale for the assessment of positive symptoms (SAPS). 
University of Iowa, Iowa City. 
28. Ashburner J, Friston KJ (2005) Unified segmentation. NeuroImage 26: 839–851. 
29. Ashburner J (2007) A fast diffeomorphic image registration algorithm. NeuroImage 
38: 95–113. 
30. Jones DK, Symms MR, Cercignani M, Howard RJ (2005) The effect of filter size on 
VBM analyses of DT-MRI data. Neuroimage 26: 546–554. 
31. Salmond CH, Ashburner J, Vargha-Khadem F, Connelly A, Gadian DG, et al. 
(2002) Distributional assumptions in voxel-based morphometry. Neuroimage 17: 
1027–1030. 
32. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH (2003) An automated method for 
neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. 
Neuroimage 19: 1233–1239. 
33. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, et al. 
(2002) Automated anatomical labeling of activations in SPM using a macroscopic 
anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15: 
273-289.  
34. Talairach J, Tournoux P (1988) Co-planar stereotaxic atlas of the human brain. 
3-Dimensional proportional system: an approach to cerebral imaging. Stuttgart 
Thieme. 
35. Lancaster JL, Summerln JL, Rainey L, Freitas CS, Fox PT (1997) The Talairach 
Daemon, a database server for Talairach Atlas Labels. NeuroImage 5: S633. 
36. Lancaster JL, Woldorff MG, Parsons LM, Liotti M, Freitas CS., et al. (2000) 
Automated Talairach atlas labels for functional brain mapping. Hum Brain Mapp 
10: 120-131. 
37. Toru M (2008) Psychotropic Manual, Third Edition. Igaku-shoin, Tokyo. (in 
Japanese) 
38. Wylie KP, Tregellas JR (2010) The role of the insula in schizophrenia. Schizophr 
 17 
Res 123: 93-104.  
39. Augustine JR (1996) Circuitry and functional aspects of the insular lobe in primates 
including humans. Brain Res Brain Res Rev 22: 229-244. 
40. Glahn DC, Laird AR, Ellison-Wright I, Thelen SM, Robinson JL, et al. (2008) 
Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic 
likelihood estimation and network analysis. Biol Psychiatry 64: 774-781. 
41. Shepherd AM, Matheson SL, Laurens KR, Carr VJ, Green MJ (2012) Systematic 
meta-analysis of insula volume in schizophrenia. Biol Psychiatry 72: 775-784. 
42. Palaniyappan L, Liddle PF (2012) Aberrant cortical gyrification in schizophrenia: a 
surface-based morphometry study. J Psychiatry Neurosci 37: 399-406. 
43. Jakob H, Beckmann H (1986) Prenatal developmental disturbances in the limbic 
allocortex in schizophrenics. J Neural Transm 65: 303-326. 
44. Pennington K, Dicker P, Hudson L, Cotter DR (2008) Evidence for reduced 
neuronal somal size within the insular cortex in schizophrenia, but not in affective 
disorders. Schizophr Res 106: 164-171. 
45. Borgwardt SJ, Riecher-Rössler A, Dazzan P, Chitnis X, Aston J, et al. (2007) 
Regional gray matter volume abnormalities in the at risk mental state. Biol 
Psychiatry 61: 1148-1156. 
46. Takahashi T, Wood SJ, Yung AR, Phillips LJ, Soulsby B, et al. (2009b) Insular 
cortex gray matter changes in individuals at ultra-high-risk of developing psychosis. 
Schizophr Res 111: 94-102.  
47. Borgwardt SJ, Picchioni MM, Ettinger U, Toulopoulou T, Murray R, et al. (2010) 
Regional gray matter volume in monozygotic twins concordant and discordant for 
schizophrenia. Biol Psychiatry 67: 956-964. 
48. Chakravarty MM, Felsky D, Tampakeras M, Lerch JP, Mulsant BH, et al. (2012) 
DISC1 and Striatal Volume: A Potential Risk Phenotype For mental Illness. Front 
Psychiatry 3: 57. 
49. Lipina TV, Niwa M, Jaaro-Peled H, Fletcher PJ, Seeman P, et al. (2010) Enhanced 
dopamine function in DISC1-L100P mutant mice: implications for schizophrenia. 
Genes Brain Behav 9: 777-789. 
50. Ballmaier M, Schlagenhauf F, Toga AW, Gallinat J, Koslowski M, et al. (2008) 
Regional patterns and clinical correlates of basal ganglia morphology in 
non-medicated schizophrenia. Schizophr Res 106: 140-147. 
 18 
51. Glenthoj A, Glenthoj BY, Mackeprang T, Pagsberg AK, Hemmingsen RP, et al. 
(2007) Basal ganglia volumes in drug-naive first-episode schizophrenia patients 
before and after short-term treatment with either a typical or an atypical 
antipsychotic drug. Psychiatry Res 154: 199-208.  
52. Gunduz H, Wu H, Ashtari M, Bogerts B, Crandall D, et al. (2002) Basal ganglia 
volumes in first-episode schizophrenia and healthy comparison subjects. Biol 
Psychiatry 51: 801-808. 
53. Li M, Chen Z, Deng W, He Z, Wang Q, et al. (2011) Volume increases in putamen 
associated with positive symptom reduction in previously drug-naive schizophrenia 
after 6 weeks antipsychotic treatment. Psychol Med 42: 1475-1483. 
54. Ebdrup BH, Skimminge A, Rasmussen H, Aggernaes B, Oranje B, et al. (2011) 
Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, 
first-episode schizophrenia patients treated with quetiapine: relationship to dose and 
symptoms. Int J Neuropsychopharmacol 14: 69-82.  
55. Borgwardt S, Smieskova R, Fusar-Poli P (2012) Gray matter pathology of 
hippocampus - a specific endophenotype for schizophrenia? Psychiatry Res 202: 
273-274.  
56. Lipska BK, Peters T, Hyde TM, Halim N, Horowitz C, et al. (2006) Expression of 
DISC1 binding partners is reduced in schizophrenia and associated with DISC1 
SNPs. Hum Mol Genet 15: 1245-1258 
57. Bis JC, DeCarli C, Smith AV, van der Lijn F, Crivello F, et al. (2012) Common 
variants at 12q14 and 12q24 are associated with hippocampal volume. Nat Genet 
44: 545-551.  
58. Stein JL, Medland SE, Vasquez AA, Hibar DP, Senstad RE, et al. (2012) 
Identification of common variants associated with human hippocampal and 
intracranial volumes. Nat Genet 44: 552-561. 
59. Sekiguchi H, Iritani S, Habuchi C, Torii Y, Kuroda K, et al. (2011) Impairment of 
the tyrosine hydroxylase neuronal network in the orbitofrontal cortex of a 
genetically modified mouse model of schizophrenia. Brain Res 1392: 47-53. 
60. Haijma SV, Van Haren N, Cahn W, Koolschijn PC, Hulshoff Pol HE, et al. (2013) 
Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr 
Bull 39: 1129-1138. 
61. Andreasen NC, Liu D, Ziebell S, Vora A, Ho BC (2013) Relapse duration, treatment 
 19 
intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI 
study. Am J Psychiatry 170: 609-615. 
62. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, et al. (2005) 
Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch 
Gen Psychiatry 62: 361-370. 
63. Anderson D, Ardekani BA, Burdick KE, Robinson DG, John M, et al. (2013) 
Overlapping and distinct gray and white matter abnormalities in schizophrenia and 
bipolar I disorder. Bipolar Disord 15: 680-693. 
 
 
  
 
  
 20 
Figure Legends 
 
Fig. 1. The YWHAE (rs28365859) genotype-by-diagnosis interaction on gray matter 
volume. The regions showing interaction in all subjects are displayed by a hot colormap. 
The color bar shows t values corresponding to the color in the figure.  
 
Fig. 2. Impact of the YWHAE genotype on gray matter volume of left insula in 
schizophrenia. Age, sex, illness duration, and medication dose were used as covariates. 
The protective C allele carriers had a significantly larger left insula than the G 
homozygotes. Anatomical localizations are displayed on the normal template MR 
images in three directions. The color bar shows t values corresponding to the color in 
the figure.  
 
Fig. 3. Impact of the YWHAE genotype on gray matter volume of the right putamen in 
healthy controls. The G allele homozygotes had a significantly larger right putamen 
than the C allele carriers. Anatomical localizations are displayed on the normal template 
MR images in three directions. The color bar shows t values corresponding to the color 
in the figure. 
 
Fig. 4. Impact of the YWHAE genotype on gray matter volume of the right hippocampus 
in schizophrenia. Age, sex, illness duration, and medication dose were used as 
covariates. The protective C allele carriers had a significantly larger right hippocampus 
than the G allele homozygotes. Anatomical localizations are displayed on the normal 
template MR images in three directions. The color bar shows t values corresponding to 
the color in the figure. 
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Table 1 
Clinical and YWHAE genotypic description of schizophrenia patients and healthy controls.
Group comparisons
C allele carriers G homozygotes C allele carriers G homozygotes
(n = 34) (n = 38) (n = 32) (n = 54)
Male/female 	
 
	 		 

  !

Age (years) 

# 
#
 
# 
# 	
Height (cm) 	
# 	#	 	# 	# 	



Body weight (kg) # 
	#		 # 	# 	

Education (years) 	#	 	#
	 	#

 	#
 			"
Parental education (years) 	#	 	
#
 	
#
 	#
 		


Age of onset (years) 
	#	 
#	   	

		
Duration of illness (years) # #   	
Duration of medication (years) 
# 
#   			
Drug dose (haloperidol equivalent, mg/day)a) 
#
 #   	
Total SAPS scoreb) 
#
 
#
   	
Total SANS scoreb) 	#
	 

#
   	
Total gray matter  volume (cm³) 	# # #
 #
 			
Values represent means ± SDs. Con, controls;  SANS, Scale for the Assessment of Negative Sympoms; SAPS, Scale for the Assessment of Positive Symptoms; Sz, schizophrenia.
a)The different typical and atypical antipsychotic dosages were converted into haloperidol equivalent according to the guidelines by Toru [37].
b)Data missing for one patient.
Schizophrenia patients Controls
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Table 2 
Effect of YWHAE genotype and genotype-by-diagnosis interaction on gray matter volume.
Brain region Contrast Covariates Clster size p 
x y z
Interaction on whole brain
Rt putamen age, sex 32 13 -5 125 < 0.0001 (uncorrected)
Lt insula age, sex -39 10 -11 108 < 0.0001 (uncorrected)
Interaction on SVC
Rt putamen age, sex 32 13 -5 168 0.001 (FWE-corrected)
Lt insula age, sex -39 10 -11 232 0.004 (FWE-corrected)
Genotype effect on SVCa)
Rt putamen ConC- > ConC+ age, sex 30 16 -1 60 0.023 (FWE-corrected)
Lt insula SzC+ > SzC- age, sex -36 8 -11 52 0.047 (FWE-corrected)
SzC+ > SzC- age, sex, doi, med -36 8 -11 68 0.037 (FWE-corrected)
ConC+, controls with C allele; ConC-, controls without C allele; doi, duration of illness; FWE, family-wise error;  Lt, left; med, daily medication dose; Rt, right;
SVC, small volume correction; SzC+, schizophrenia patients with C allele; SzC-, schizophrenia without C allele.
a)There were no suprathreshold clusters for other contrasts.
Talairach coordinate
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Table 3
Effect of YWHAE genotype on right hippocampal gray matter volume.
Contrasta) Covariates Clster size FWE p
x y z
C+>C- age, sex 24 -35 0 120 0.009
 age, sex 20 -33 3 78 0.009
age, sex, doi, med 20 -33 3 120 0.002
C+, subjects with C allele; C-, subjects without C allele;  doi, duration of illness; FWE, family-wise error;  
med, daily medication dose; SzC+, schizophrenia patients with C allele; SzC-, schizophrenia patients without C allele.
a)There were no suprathreshold clusters for other contrasts.
Talairach coordinate
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